Click for best price
Drugs for Vulvovaginal Cidiasis Market Size, Share 2023
| Market size in 2022 |
US$ 840.2 million
|
Forecast Market size by 2029 |
US$ 928.4 million
|
| Growth Rate |
CAGR of 1.4% |
Number of Pages |
77 Pages |
The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.
Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.
This report aims to provide a comprehensive presentation of the global market for Drugs for Vulvovaginal Candidiasis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Vulvovaginal Candidiasis. This report contains market size and forecasts of Drugs for Vulvovaginal Candidiasis in global, including the following market information:
Global Drugs for Vulvovaginal Candidiasis Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Drugs for Vulvovaginal Candidiasis Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Drugs for Vulvovaginal Candidiasis companies in 2022 (%)
The global Drugs for Vulvovaginal Candidiasis market was valued at US$ 840.2 million in 2022 and is projected to reach US$ 928.4 million by 2029, at a CAGR of 1.4% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The main manufacturers of Drugs for Vulvovaginal Candidiasis are Bayer, J & J, Pfizer, Perrigo, Effik, etc. The top three manufacturers in the world occupy about 40% of the market share.
The Asia-Pacific region is the world's largest market, with a market share of about 45%, followed by North America with nearly 20%
We surveyed the Drugs for Vulvovaginal Candidiasis manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Drugs for Vulvovaginal Candidiasis Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Drugs for Vulvovaginal Candidiasis Market Segment Percentages, by Type, 2022 (%)
Cream
Pessary
Other
Global Drugs for Vulvovaginal Candidiasis Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Drugs for Vulvovaginal Candidiasis Market Segment Percentages, by Application, 2022 (%)
Hospital & Clinic
Pharmacy
Global Drugs for Vulvovaginal Candidiasis Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Drugs for Vulvovaginal Candidiasis Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Drugs for Vulvovaginal Candidiasis revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Drugs for Vulvovaginal Candidiasis revenues share in global market, 2022 (%)
Key companies Drugs for Vulvovaginal Candidiasis sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Drugs for Vulvovaginal Candidiasis sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group
Outline of Major Chapters:
Chapter 1: Introduces the definition of Drugs for Vulvovaginal Candidiasis, market overview.
Chapter 2: Global Drugs for Vulvovaginal Candidiasis market size in revenue and volume.
Chapter 3: Detailed analysis of Drugs for Vulvovaginal Candidiasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Drugs for Vulvovaginal Candidiasis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Drugs for Vulvovaginal Candidiasis capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Drugs for Vulvovaginal Candidiasis Market, Global Outlook and Forecast 2023-2029 |
| Market size in 2022 |
US$ 840.2 million
|
| Forecast Market size by 2029 |
US$ 928.4 million
|
| Growth Rate |
CAGR of 1.4% |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
77 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Drugs for Vulvovaginal Candidiasis Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Drugs for Vulvovaginal Candidiasis Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Drugs for Vulvovaginal Candidiasis Overall Market Size
2.1 Global Drugs for Vulvovaginal Candidiasis Market Size: 2022 VS 2029
2.2 Global Drugs for Vulvovaginal Candidiasis Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Drugs for Vulvovaginal Candidiasis Sales: 2018-2029
3 Company Landscape
3.1 Top Drugs for Vulvovaginal Candidiasis Players in Global Market
3.2 Top Global Drugs for Vulvovaginal Candidiasis Companies Ranked by Revenue
3.3 Global Drugs for Vulvovaginal Candidiasis Revenue by Companies
3.4 Global Drugs for Vulvovaginal Candidiasis Sales by Companies
3.5 Global Drugs for Vulvovaginal Candidiasis Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Drugs for Vulvovaginal Candidiasis Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Drugs for Vulvovaginal Candidiasis Product Type
3.8 Tier 1, Tier 2 and Tier 3 Drugs for Vulvovaginal Candidiasis Players in Global Market
3.8.1 List of Global Tier 1 Drugs for Vulvovaginal Candidiasis Companies
3.8.2 List of Global Tier 2 and Tier 3 Drugs for Vulvovaginal Candidiasis Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Drugs for Vulvovaginal Candidiasis Market Size Markets, 2022 & 2029
4.1.2 Cream
4.1.3 Pessary
4.1.4 Other
4.2 By Type - Global Drugs for Vulvovaginal Candidiasis Revenue & Forecasts
4.2.1 By Type - Global Drugs for Vulvovaginal Candidiasis Revenue, 2018-2023
4.2.2 By Type - Global Drugs for Vulvovaginal Candidiasis Revenue, 2024-2029
4.2.3 By Type - Global Drugs for Vulvovaginal Candidiasis Revenue Market Share, 2018-2029
4.3 By Type - Global Drugs for Vulvovaginal Candidiasis Sales & Forecasts
4.3.1 By Type - Global Drugs for Vulvovaginal Candidiasis Sales, 2018-2023
4.3.2 By Type - Global Drugs for Vulvovaginal Candidiasis Sales, 2024-2029
4.3.3 By Type - Global Drugs for Vulvovaginal Candidiasis Sales Market Share, 2018-2029
4.4 By Type - Global Drugs for Vulvovaginal Candidiasis Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Drugs for Vulvovaginal Candidiasis Market Size, 2022 & 2029
5.1.2 Hospital & Clinic
5.1.3 Pharmacy
5.2 By Application - Global Drugs for Vulvovaginal Candidiasis Revenue & Forecasts
5.2.1 By Application - Global Drugs for Vulvovaginal Candidiasis Revenue, 2018-2023
5.2.2 By Application - Global Drugs for Vulvovaginal Candidiasis Revenue, 2024-2029
5.2.3 By Application - Global Drugs for Vulvovaginal Candidiasis Revenue Market Share, 2018-2029
5.3 By Application - Global Drugs for Vulvovaginal Candidiasis Sales & Forecasts
5.3.1 By Application - Global Drugs for Vulvovaginal Candidiasis Sales, 2018-2023
5.3.2 By Application - Global Drugs for Vulvovaginal Candidiasis Sales, 2024-2029
5.3.3 By Application - Global Drugs for Vulvovaginal Candidiasis Sales Market Share, 2018-2029
5.4 By Application - Global Drugs for Vulvovaginal Candidiasis Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region - Global Drugs for Vulvovaginal Candidiasis Market Size, 2022 & 2029
6.2 By Region - Global Drugs for Vulvovaginal Candidiasis Revenue & Forecasts
6.2.1 By Region - Global Drugs for Vulvovaginal Candidiasis Revenue, 2018-2023
6.2.2 By Region - Global Drugs for Vulvovaginal Candidiasis Revenue, 2024-2029
6.2.3 By Region - Global Drugs for Vulvovaginal Candidiasis Revenue Market Share, 2018-2029
6.3 By Region - Global Drugs for Vulvovaginal Candidiasis Sales & Forecasts
6.3.1 By Region - Global Drugs for Vulvovaginal Candidiasis Sales, 2018-2023
6.3.2 By Region - Global Drugs for Vulvovaginal Candidiasis Sales, 2024-2029
6.3.3 By Region - Global Drugs for Vulvovaginal Candidiasis Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Drugs for Vulvovaginal Candidiasis Revenue, 2018-2029
6.4.2 By Country - North America Drugs for Vulvovaginal Candidiasis Sales, 2018-2029
6.4.3 US Drugs for Vulvovaginal Candidiasis Market Size, 2018-2029
6.4.4 Canada Drugs for Vulvovaginal Candidiasis Market Size, 2018-2029
6.4.5 Mexico Drugs for Vulvovaginal Candidiasis Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Drugs for Vulvovaginal Candidiasis Revenue, 2018-2029
6.5.2 By Country - Europe Drugs for Vulvovaginal Candidiasis Sales, 2018-2029
6.5.3 Germany Drugs for Vulvovaginal Candidiasis Market Size, 2018-2029
6.5.4 France Drugs for Vulvovaginal Candidiasis Market Size, 2018-2029
6.5.5 U.K. Drugs for Vulvovaginal Candidiasis Market Size, 2018-2029
6.5.6 Italy Drugs for Vulvovaginal Candidiasis Market Size, 2018-2029
6.5.7 Russia Drugs for Vulvovaginal Candidiasis Market Size, 2018-2029
6.5.8 Nordic Countries Drugs for Vulvovaginal Candidiasis Market Size, 2018-2029
6.5.9 Benelux Drugs for Vulvovaginal Candidiasis Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Drugs for Vulvovaginal Candidiasis Revenue, 2018-2029
6.6.2 By Region - Asia Drugs for Vulvovaginal Candidiasis Sales, 2018-2029
6.6.3 China Drugs for Vulvovaginal Candidiasis Market Size, 2018-2029
6.6.4 Japan Drugs for Vulvovaginal Candidiasis Market Size, 2018-2029
6.6.5 South Korea Drugs for Vulvovaginal Candidiasis Market Size, 2018-2029
6.6.6 Southeast Asia Drugs for Vulvovaginal Candidiasis Market Size, 2018-2029
6.6.7 India Drugs for Vulvovaginal Candidiasis Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Drugs for Vulvovaginal Candidiasis Revenue, 2018-2029
6.7.2 By Country - South America Drugs for Vulvovaginal Candidiasis Sales, 2018-2029
6.7.3 Brazil Drugs for Vulvovaginal Candidiasis Market Size, 2018-2029
6.7.4 Argentina Drugs for Vulvovaginal Candidiasis Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Drugs for Vulvovaginal Candidiasis Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales, 2018-2029
6.8.3 Turkey Drugs for Vulvovaginal Candidiasis Market Size, 2018-2029
6.8.4 Israel Drugs for Vulvovaginal Candidiasis Market Size, 2018-2029
6.8.5 Saudi Arabia Drugs for Vulvovaginal Candidiasis Market Size, 2018-2029
6.8.6 UAE Drugs for Vulvovaginal Candidiasis Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Bayer
7.1.1 Bayer Company Summary
7.1.2 Bayer Business Overview
7.1.3 Bayer Drugs for Vulvovaginal Candidiasis Major Product Offerings
7.1.4 Bayer Drugs for Vulvovaginal Candidiasis Sales and Revenue in Global (2018-2023)
7.1.5 Bayer Key News & Latest Developments
7.2 Perrigo
7.2.1 Perrigo Company Summary
7.2.2 Perrigo Business Overview
7.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Major Product Offerings
7.2.4 Perrigo Drugs for Vulvovaginal Candidiasis Sales and Revenue in Global (2018-2023)
7.2.5 Perrigo Key News & Latest Developments
7.3 J & J
7.3.1 J & J Company Summary
7.3.2 J & J Business Overview
7.3.3 J & J Drugs for Vulvovaginal Candidiasis Major Product Offerings
7.3.4 J & J Drugs for Vulvovaginal Candidiasis Sales and Revenue in Global (2018-2023)
7.3.5 J & J Key News & Latest Developments
7.4 Pfizer
7.4.1 Pfizer Company Summary
7.4.2 Pfizer Business Overview
7.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Major Product Offerings
7.4.4 Pfizer Drugs for Vulvovaginal Candidiasis Sales and Revenue in Global (2018-2023)
7.4.5 Pfizer Key News & Latest Developments
7.5 Bristol-Myers Squibb
7.5.1 Bristol-Myers Squibb Company Summary
7.5.2 Bristol-Myers Squibb Business Overview
7.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Major Product Offerings
7.5.4 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales and Revenue in Global (2018-2023)
7.5.5 Bristol-Myers Squibb Key News & Latest Developments
7.6 Effik
7.6.1 Effik Company Summary
7.6.2 Effik Business Overview
7.6.3 Effik Drugs for Vulvovaginal Candidiasis Major Product Offerings
7.6.4 Effik Drugs for Vulvovaginal Candidiasis Sales and Revenue in Global (2018-2023)
7.6.5 Effik Key News & Latest Developments
7.7 Teva
7.7.1 Teva Company Summary
7.7.2 Teva Business Overview
7.7.3 Teva Drugs for Vulvovaginal Candidiasis Major Product Offerings
7.7.4 Teva Drugs for Vulvovaginal Candidiasis Sales and Revenue in Global (2018-2023)
7.7.5 Teva Key News & Latest Developments
7.8 Sanofi
7.8.1 Sanofi Company Summary
7.8.2 Sanofi Business Overview
7.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Major Product Offerings
7.8.4 Sanofi Drugs for Vulvovaginal Candidiasis Sales and Revenue in Global (2018-2023)
7.8.5 Sanofi Key News & Latest Developments
7.9 Cisen Pharmaceutical
7.9.1 Cisen Pharmaceutical Company Summary
7.9.2 Cisen Pharmaceutical Business Overview
7.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Major Product Offerings
7.9.4 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales and Revenue in Global (2018-2023)
7.9.5 Cisen Pharmaceutical Key News & Latest Developments
7.10 Kingyork Group
7.10.1 Kingyork Group Company Summary
7.10.2 Kingyork Group Business Overview
7.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Major Product Offerings
7.10.4 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales and Revenue in Global (2018-2023)
7.10.5 Kingyork Group Key News & Latest Developments
8 Global Drugs for Vulvovaginal Candidiasis Production Capacity, Analysis
8.1 Global Drugs for Vulvovaginal Candidiasis Production Capacity, 2018-2029
8.2 Drugs for Vulvovaginal Candidiasis Production Capacity of Key Manufacturers in Global Market
8.3 Global Drugs for Vulvovaginal Candidiasis Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Drugs for Vulvovaginal Candidiasis Supply Chain Analysis
10.1 Drugs for Vulvovaginal Candidiasis Industry Value Chain
10.2 Drugs for Vulvovaginal Candidiasis Upstream Market
10.3 Drugs for Vulvovaginal Candidiasis Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Drugs for Vulvovaginal Candidiasis Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Drugs for Vulvovaginal Candidiasis in Global Market
Table 2. Top Drugs for Vulvovaginal Candidiasis Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Drugs for Vulvovaginal Candidiasis Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Companies, 2018-2023
Table 5. Global Drugs for Vulvovaginal Candidiasis Sales by Companies, (K Units), 2018-2023
Table 6. Global Drugs for Vulvovaginal Candidiasis Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Drugs for Vulvovaginal Candidiasis Price (2018-2023) & (USD/Unit)
Table 8. Global Manufacturers Drugs for Vulvovaginal Candidiasis Product Type
Table 9. List of Global Tier 1 Drugs for Vulvovaginal Candidiasis Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Drugs for Vulvovaginal Candidiasis Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Drugs for Vulvovaginal Candidiasis Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Drugs for Vulvovaginal Candidiasis Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Drugs for Vulvovaginal Candidiasis Sales (K Units), 2018-2023
Table 15. By Type - Global Drugs for Vulvovaginal Candidiasis Sales (K Units), 2024-2029
Table 16. By Application ? Global Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Drugs for Vulvovaginal Candidiasis Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Drugs for Vulvovaginal Candidiasis Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Drugs for Vulvovaginal Candidiasis Sales (K Units), 2018-2023
Table 20. By Application - Global Drugs for Vulvovaginal Candidiasis Sales (K Units), 2024-2029
Table 21. By Region ? Global Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Drugs for Vulvovaginal Candidiasis Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Drugs for Vulvovaginal Candidiasis Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Drugs for Vulvovaginal Candidiasis Sales (K Units), 2018-2023
Table 25. By Region - Global Drugs for Vulvovaginal Candidiasis Sales (K Units), 2024-2029
Table 26. By Country - North America Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Drugs for Vulvovaginal Candidiasis Sales, (K Units), 2018-2023
Table 29. By Country - North America Drugs for Vulvovaginal Candidiasis Sales, (K Units), 2024-2029
Table 30. By Country - Europe Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Drugs for Vulvovaginal Candidiasis Sales, (K Units), 2018-2023
Table 33. By Country - Europe Drugs for Vulvovaginal Candidiasis Sales, (K Units), 2024-2029
Table 34. By Region - Asia Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Drugs for Vulvovaginal Candidiasis Sales, (K Units), 2018-2023
Table 37. By Region - Asia Drugs for Vulvovaginal Candidiasis Sales, (K Units), 2024-2029
Table 38. By Country - South America Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Drugs for Vulvovaginal Candidiasis Sales, (K Units), 2018-2023
Table 41. By Country - South America Drugs for Vulvovaginal Candidiasis Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales, (K Units), 2024-2029
Table 46. Bayer Company Summary
Table 47. Bayer Drugs for Vulvovaginal Candidiasis Product Offerings
Table 48. Bayer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 49. Bayer Key News & Latest Developments
Table 50. Perrigo Company Summary
Table 51. Perrigo Drugs for Vulvovaginal Candidiasis Product Offerings
Table 52. Perrigo Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 53. Perrigo Key News & Latest Developments
Table 54. J & J Company Summary
Table 55. J & J Drugs for Vulvovaginal Candidiasis Product Offerings
Table 56. J & J Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 57. J & J Key News & Latest Developments
Table 58. Pfizer Company Summary
Table 59. Pfizer Drugs for Vulvovaginal Candidiasis Product Offerings
Table 60. Pfizer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 61. Pfizer Key News & Latest Developments
Table 62. Bristol-Myers Squibb Company Summary
Table 63. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Offerings
Table 64. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 65. Bristol-Myers Squibb Key News & Latest Developments
Table 66. Effik Company Summary
Table 67. Effik Drugs for Vulvovaginal Candidiasis Product Offerings
Table 68. Effik Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 69. Effik Key News & Latest Developments
Table 70. Teva Company Summary
Table 71. Teva Drugs for Vulvovaginal Candidiasis Product Offerings
Table 72. Teva Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 73. Teva Key News & Latest Developments
Table 74. Sanofi Company Summary
Table 75. Sanofi Drugs for Vulvovaginal Candidiasis Product Offerings
Table 76. Sanofi Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 77. Sanofi Key News & Latest Developments
Table 78. Cisen Pharmaceutical Company Summary
Table 79. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Offerings
Table 80. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 81. Cisen Pharmaceutical Key News & Latest Developments
Table 82. Kingyork Group Company Summary
Table 83. Kingyork Group Drugs for Vulvovaginal Candidiasis Product Offerings
Table 84. Kingyork Group Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 85. Kingyork Group Key News & Latest Developments
Table 86. Drugs for Vulvovaginal Candidiasis Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 87. Global Drugs for Vulvovaginal Candidiasis Capacity Market Share of Key Manufacturers, 2021-2023
Table 88. Global Drugs for Vulvovaginal Candidiasis Production by Region, 2018-2023 (K Units)
Table 89. Global Drugs for Vulvovaginal Candidiasis Production by Region, 2024-2029 (K Units)
Table 90. Drugs for Vulvovaginal Candidiasis Market Opportunities & Trends in Global Market
Table 91. Drugs for Vulvovaginal Candidiasis Market Drivers in Global Market
Table 92. Drugs for Vulvovaginal Candidiasis Market Restraints in Global Market
Table 93. Drugs for Vulvovaginal Candidiasis Raw Materials
Table 94. Drugs for Vulvovaginal Candidiasis Raw Materials Suppliers in Global Market
Table 95. Typical Drugs for Vulvovaginal Candidiasis Downstream
Table 96. Drugs for Vulvovaginal Candidiasis Downstream Clients in Global Market
Table 97. Drugs for Vulvovaginal Candidiasis Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Drugs for Vulvovaginal Candidiasis Segment by Type in 2022
Figure 2. Drugs for Vulvovaginal Candidiasis Segment by Application in 2022
Figure 3. Global Drugs for Vulvovaginal Candidiasis Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Drugs for Vulvovaginal Candidiasis Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Drugs for Vulvovaginal Candidiasis Revenue, 2018-2029 (US$, Mn)
Figure 7. Drugs for Vulvovaginal Candidiasis Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Drugs for Vulvovaginal Candidiasis Revenue in 2022
Figure 9. By Type - Global Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Drugs for Vulvovaginal Candidiasis Revenue Market Share, 2018-2029
Figure 11. By Type - Global Drugs for Vulvovaginal Candidiasis Sales Market Share, 2018-2029
Figure 12. By Type - Global Drugs for Vulvovaginal Candidiasis Price (USD/Unit), 2018-2029
Figure 13. By Application - Global Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Drugs for Vulvovaginal Candidiasis Revenue Market Share, 2018-2029
Figure 15. By Application - Global Drugs for Vulvovaginal Candidiasis Sales Market Share, 2018-2029
Figure 16. By Application - Global Drugs for Vulvovaginal Candidiasis Price (USD/Unit), 2018-2029
Figure 17. By Region - Global Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Drugs for Vulvovaginal Candidiasis Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Drugs for Vulvovaginal Candidiasis Revenue Market Share, 2018-2029
Figure 20. By Region - Global Drugs for Vulvovaginal Candidiasis Sales Market Share, 2018-2029
Figure 21. By Country - North America Drugs for Vulvovaginal Candidiasis Revenue Market Share, 2018-2029
Figure 22. By Country - North America Drugs for Vulvovaginal Candidiasis Sales Market Share, 2018-2029
Figure 23. US Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Drugs for Vulvovaginal Candidiasis Sales Market Share, 2018-2029
Figure 28. Germany Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2018-2029
Figure 29. France Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Drugs for Vulvovaginal Candidiasis Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Drugs for Vulvovaginal Candidiasis Sales Market Share, 2018-2029
Figure 37. China Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2018-2029
Figure 41. India Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Drugs for Vulvovaginal Candidiasis Revenue Market Share, 2018-2029
Figure 43. By Country - South America Drugs for Vulvovaginal Candidiasis Sales Market Share, 2018-2029
Figure 44. Brazil Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Drugs for Vulvovaginal Candidiasis Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Market Share, 2018-2029
Figure 48. Turkey Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2018-2029
Figure 52. Global Drugs for Vulvovaginal Candidiasis Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Drugs for Vulvovaginal Candidiasis by Region, 2022 VS 2029
Figure 54. Drugs for Vulvovaginal Candidiasis Industry Value Chain
Figure 55. Marketing Channels
